3
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Within-subject variation of elastase/α1-protease inhibitor complexes and lactoferrin in plasma

Pages 611-616 | Received 25 Sep 1992, Accepted 22 May 1993, Published online: 28 Aug 2009
 

Abstract

Antonsen S. Within-subject variation of elastase/a!-protease inhibitor complexes and lactoferrin in plasma. Scand J Clin Lab Invest 1993; 53: 611-616.

Several studies have shown increased plasma concentrations of neutrophil elas-tase in complex with a)-protease inhibitor and/or lactoferrin in inflammatory conditions, and serial measurements have been advocated in order to follow disease activity. However, data on the magnitude of the within-subject variation are necessary for evaluation of the significance of changes in results obtained on analysis of serial samples. Within-subject variation of elastase/oj)-protease inhibitor complexes and lactoferrin over a short time was studied in six young men who had blood samples drawn every 4h over 2 days. Within-subject variation over a longer time was investigated in 12 healthy adults, 6 females and 6 males, who had blood samples drawn in the morning once a week for 10 weeks. From five of the females and five of the males, blood samples were also drawn every morning on 5 consecutive days during 1 week. Within-subject variations over hours, days, and weeks were estimated as 0.050, 0.124, and 0.148 for elastase/ai-protease inhibitor complexes and as 0.101, 0.119, and 0.143 for lactoferrin. A tendency towards variation of LAC with menstrual cycle in fertile females was noticed. From within-subject variation, between-subject variation and analytical variation, indices of individuality were calculated as 1.1 and 1.8 for elastase/a]-protease inhibitor complexes and lactoferrin, respectively. This means that within-subject variation for lactoferrin is quite small compared to between-subject variation, and the usefulness of reference limits is very limited, when interpreting results from individual patients. For elastase/o)-protease inhibitor complexes, the use of reference limits might be more appropriate, although still not optimal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.